6 terminated. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 6 |
| Phase 1 | 1 | Terminated 1 |
Follow Pulmonary Aspergillosis: new trials by email Literature Review of Pulmonary Aspergillosis trials Research Report on Pulmonary Aspergillosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA Itraconazole Powder, Placebo - ABPA | Phase 2 | Terminated | Pulmatrix Inc. | 8 | 2023-02-01 | 2024-04-02 |
| Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds fosmanogepix - Invasive Fungal Infections | Phase 2 | Terminated | Basilea Pharmaceutica | 21 | 2020-01-04 | 2025-09-16 |
| Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis PUR1900, Placebo - Allergic Bronchopulmonary Aspergillosis | Phase 2 | Terminated | Pulmatrix Inc. | 7 | 2019-07-31 | 2021-08-27 |
| Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis SCY-078, Voriconazole, Oral Placebo Tablets - Invasive Pulmonary Aspergillosis | Phase 2 | Terminated | Scynexis, Inc. | 22 | 2019-01-22 | 2024-08-09 |
| VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B - Invasive Aspergillosis, Invasive Pulmonary Aspergillosis | Phase 2 | Terminated | Vical | 4 | 2018-02-20 | 2019-02-27 |
| Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients Placebo, QBW251 - Cystic Fibrosis | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 153 | 2012-07-31 | 2020-12-30 |
Aspergillosis (3) · Aspergillosis, Allergic Bronchopulmonary (3) · Invasive Pulmonary Aspergillosis (2) · Asthma (1) · COVID-19 (1) · Cystic Fibrosis (1) · Invasive Fungal Infections (1) · Mycoses (1)
Bacterial Infections and Mycoses (6) · Infections (6) · Lung Diseases (6) · Lung Diseases, Fungal (6) · Respiratory Tract Diseases (6) · Mycoses (5) · Respiratory Tract Infections (4) · Aspergillosis (3) · Hypersensitivity (3) · Hypersensitivity, Immediate (3) · Immune System Diseases (3) · Respiratory Hypersensitivity (3) · Invasive Fungal Infections (2) · Bronchial Diseases (1)
Voriconazole (1) · ibrexafungerp (1) · icenticaftor (1) · isavuconazole (1) · liposomal amphotericin B (1)
Pulmatrix Inc. (2) · Basilea Pharmaceutica (1) · Novartis Pharmaceuticals (1) · Scynexis, Inc. (1) · Vical (1)
United States (6) · Belgium (4) · Germany (4) · France (3) · United Kingdom (3) · Australia (2) · Canada (2) · India (1) · Ireland (1) · Israel (1) · Poland (1) · Romania (1) · South Africa (1) · South Korea (1)
Chris Cabell, MD (1) · David Angulo, MD (1) · David Denning, FRCP, FRC Path, FIDSA, FMedSci (1) · Mammen P Mammen, MD, FIDSA (1) · Marc Engelhardt (1) · William J. Calhoun, MD (1)
2017 (1), 2018 (1), 2019 (1)